Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Food HypersensitivityHypersensitivityImmediate HypersensitivityPeanut Hypersensitivity
Interventions
BIOLOGICAL

E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3

Up to 7 mL solution administered rectally

Trial Locations (2)

10029

Mount Sinai Medical Center, New York

21205

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

Consortium of Food Allergy Research

OTHER

lead

Allertein Therapeutics, LLC

INDUSTRY